Cargando…

Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review

Dasatinib is a potent and effective second‐generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib‐resistant or imatinib‐intolerant breakpoint cluster region‐Abelson (BCR‐ABL)‐positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome‐positiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Chao‐Chin, Hsu, Jui‐Feng, Wu, Kuan‐Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103079/ https://www.ncbi.nlm.nih.gov/pubmed/33976882 http://dx.doi.org/10.1002/rcr2.753

Ejemplares similares

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia
por: Kelly, Ryan L., et al.
Publicado: (2022)

Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review
por: Liu, Qinqin, et al.
Publicado: (2023)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Dasatinib-Induced Chylothorax: A Clinical Laboratory’s Perspective
por: Martínez, Rafael J. García, et al.
Publicado: (2023)

Dasatinib: Chylothorax and right pleural effusion: case report
Publicado: (2019)

Dasatinib-induced pleural effusion: Chylothorax, an option to consider
por: Ferreiro, Lucía, et al.
Publicado: (2016)

Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review
por: Paul, Theresa, et al.
Publicado: (2021)

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
por: Giallongo, Cesarina, et al.
Publicado: (2017)

Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
por: Yu, Lu, et al.
Publicado: (2019)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
por: Halbach, Sebastian, et al.
Publicado: (2013)

Dasatinib-Induced Chylothorax Beyond 5 Years of Treatment: Is There Actually Any Limit?
por: Garcia-Zamalloa, Alberto, et al.
Publicado: (2023)

Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine “Goreisan”
por: Sasaki, Hisashi, et al.
Publicado: (2019)

Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature
por: Alharbi, Bader, et al.
Publicado: (2018)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia
por: Vráblová, Lucia, et al.
Publicado: (2023)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro
por: Amrein, Lilian, et al.
Publicado: (2009)

What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
por: Jamison, Caroline, et al.
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
por: Chang, Ming-Chin, et al.
Publicado: (2019)

Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report
por: Pilalas, Dimitrios, et al.
Publicado: (2020)

Dasatinib-Induced Rhabdomyolysis in a 33-Year-Old Patient with Chronic Myeloid Leukemia
por: Joel Chandranesan, Andrew Stevenson, et al.
Publicado: (2018)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia
por: Yassin, Mohamed A, et al.
Publicado: (2015)

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015)

Postpartum Chylothorax: A Case Report and Review of the Literature
por: Moguillansky, Natalia, et al.
Publicado: (2023)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
por: Tarantini, Francesco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k6ocqska4pem8648n8il82rikj